Floatz logo

pf-08634404

Rectal Diseases

PfizerPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Rectal Diseases cohort.

Asset / SponsorPhaseRating
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2B
Eloxatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2B
Catequentinib
Zhejiang University
Phase 2B
Ddavp
Laboratorio Elea Phoenix S.A.
Phase 2NR

Same molecule, other indications

pf-08634404 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
neoplasmDormant
B
Indicative ·
60 / 100
View asset →
intestinal neoplasmDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →